Hypersensitivity Reactions Secondary to Dupilumab in Two Patients with Moderate to Severe Atopic Dermatitis

Abstract

Dupilumab is a human monoclonal IgG4 antibody that is widely used to treat atopic dermatitis. Dupilumab was recently FDA approved to treat moderate to severe atopic dermatitis. Here we decribe two cases of patients with moderate to severe atopic dermatitis who developed an acute hypersensitivity reaction within hours of their second dose of dupilumab.

Lichenoid-granulomatous drug reactions to dupilumab: A report of 2 cases

“…1 There are several reports of drug hypersensitivity reactions (DHR) to dupilumab, including conjunctivitis, psoriasiform, eczematous, and lichenoid eruptions. 2 , 3 , 4 It has been theorized that dupilumab-mediated inhibition of Th2 pathways may upregulate Th1/Th17 dominated response in patients with atopic dermatitis (AD); a Th1 hyperresponse can lead to development of psoriasiform dermatitis. 4 Herein, we report 2 patients, who developed lichenoid granulomatous eruptions several months after dupilumab initiation, with complete resolution upon discontinuation, supportive of DHR.…”